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The first case of feline primary aldosteronism was described in 1983. Since then, the disease 
has been diagnosed with increased frequency. Although no data are available concerning the 
true prevalence, it is assumed that the disease is more common than initially thought. This 
hypothesis is based on data from human medicine, where increased disease awareness led to a 
more systematic screening of the hypertensive population resulting in a strong increase in 
prevalence. Primary aldosteronism however, seems to be very rare in dogs.  
In human medicine, approximately two-thirds of patients have bilateral idiopathic adrenal 
hyperplasia while about one third has aldosterone-producing adenomas (aldosteronomas). 
Typical findings are systemic hypertension, hypokalemia and metabolic acidosis. However, 
because screening for the disease is becoming more systematic and the diagnosis is generally 
made earlier, the prevalence of hypokalemia is decreasing and nowadays the majority of 
patients are normokalemic at the time of diagnosis. Currently, 5 to 10% of the general 
hypertensive population and 20% of patients with severe or resistant hypertension are 
assumed to suffer from primary aldosteronism. The degree of hypertension is usually 
moderate to severe, and patients with aldosteronoma tend to have higher blood pressure than 
patients with idiopathic aldosteronism. 
The consequences of increased aldosterone concentration are retention of sodium and water in 
the distal and collecting tubules of the kidneys. This results in increased intravascular volume 
and increased urinary potassium and hydrogen excretion. Excessive concentrations of 
circulating aldosterone also induce vasoconstriction and lead to an increase in peripheral 
vascular resistance. The two central mechanisms responsible for the development of 
hypertension in primary aldosteronism are expansion of plasma and extracellular fluid volume 
and increase in total peripheral vascular resistance. Aldosterone per se has pro-inflammatory 
and pro-fibrotic properties resulting in vascular, cardiac and renal lesions. The 
pathophysiology of aldosterone-associated hypertension in cats is thought to be identical to 
humans.  
The majority of cats with primary aldosteronism have been shown to have unilateral 
carcinomas, while adenomas and hyperplasia have been less frequently reported. Clinical 
signs include weakness with associated cervical ventroflexion, mydriasis and blindness 
because of hypertensive retinopathy; some cats also show polyuria/polydipsia. 
Almost all cats described to date have been hypokalemic at the time of diagnosis. However, as 
in human medicine, it may be possible that aldosteronism is overlooked in cats with normal 
potassium levels. A more systematic screening for primary aldosteronism may improve 
diagnosis and thus increase the prevalence of the disease. Based on data available to date, the 
prevalence of hypertension in cats with primary aldosteronism appears to be high. Blood 
pressure was recorded in 30 cases, 26 of which were hypertensive. The severity ranged from 
mild to severe (185-270 mmHg), and the most common sequels were retinal detachment and 
ocular bleeding. Definitive diagnosis requires demonstration of inappropriately elevated 
aldosterone concentration with low plasma rennin activity. The disease is often suspected only 
after the finding of an adrenal mass by ultrasonography. 
Initial treatment should be directed towards alleviation of hypertension and hypokalemia by 
using an aldosterone antagonist (spironolactone 2.5 mg/kg q24h or 6.25 mg/cat q12h PO) and 
a calcium channel blocker (amlodipine besylate 0.625-1.25 mg/cat q24h PO), and substituting 
potassium as needed. Subsequent adrenalectomy is the treatment of choice for animals 
without tumor metastasis. In the few cases described in the literature, as well as in the cases 
seen at our hospital, hypertension resolved after surgery. In cases in which adrenalectomy is 
not feasible (e.g. metastasized tumor, bilateral tumor or hyperplasia), medical treatment with 
spironolactone and amlodipine besylate should be continued. The two drugs combined seem 
to lead to resolution of hypertension in most cases. 
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